COHANCE vs DIVISLAB: Stock Comparison

Cohance Lifesciences Limited vs Divis Laboratories Ltd

Live data: 22 July 2026, 3:01 PM IST • Source: NSE and company filings

Divis Laboratories Ltd is the larger company by market capitalisation. Divis Laboratories Ltd shows a lower P/E, a higher ROE and a higher dividend yield. These are relative readings on individual metrics — weigh valuation against growth, margins, leverage and capital efficiency rather than treating any single number as decisive.

Side-by-side comparison of Cohance Lifesciences Limited and Divis Laboratories Ltd on live price, valuation, growth, profitability, leverage and quarterly shareholding. Highlighted values mark the more favourable of the two on that metric's usual reading; a single metric is never the full story.

On standard readings, COHANCE is more favourable on 1 of 13 scored metrics and DIVISLAB on 12These counts are context-free and are not an overall rating.

Key Differences

Market Cap
DIVISLAB is the larger company
₹1.96 L Cr vs ₹16,812 Cr
P/E Ratio
DIVISLAB has a lower P/E
75.8x vs 95.36x
P/B Ratio
COHANCE has a lower P/B
4.37x vs 11.61x
EPS
DIVISLAB has higher earnings per share
₹96.6 vs ₹4.69
Dividend Yield
DIVISLAB has a higher dividend yield
0.41% vs 0%
Revenue Growth (TTM YoY)
DIVISLAB has faster revenue growth
9.5% vs -26.3%
EPS Growth (TTM YoY)
DIVISLAB has faster EPS growth
13.6% vs -89%
Qtr Sales Growth
DIVISLAB has stronger quarterly sales growth
9.52% vs -26.3%

Each difference is a single, relative reading — StockeZee does not name an overall winner.

Profile

MetricCOHANCEDIVISLAB
SectorHealthcareHealthcare
IndustryPharmaceuticalsPharmaceuticals

Price

MetricCOHANCEDIVISLAB
Live Price₹437.45₹7,389
Day Change-1.84%0.8%
Volume4.99 L3.25 L
52-Week High₹1,079₹7,438.5
52-Week Low₹266.7₹5,636.5
Distance from 52W High-59.46%-0.67%

Valuation

MetricCOHANCEDIVISLAB
Market Cap₹16,812 Cr₹1.96 L Cr
P/E Ratio95.36x75.8x
P/B Ratio4.37x11.61x
EPS₹4.69₹96.6
Book Value₹102.03₹631.37
Dividend Yield0%0.41%

Growth

MetricCOHANCEDIVISLAB
Revenue Growth (TTM YoY)-26.3%9.5%
EPS Growth (TTM YoY)-89%13.6%
Qtr Sales Growth-26.3%9.52%
Qtr Profit Growth-86.6%13.4%

Profitability & Leverage

MetricCOHANCEDIVISLAB
ROE7.04%16.5%
ROCE8.35%22%
Net Margin7.9%24.36%
Operating Margin18.8%32.6%
Debt to Equity0.1x0x

Shareholding

As of Jun 2026 • change vs previous quarter
MetricCOHANCEDIVISLAB
Promoter Holding0%51.88%
FII Holding6.5% 0.91 pp20.2% 0.09 pp
DII Holding20.09% 1.7 pp19.38% 0.16 pp
Public Holding15.92% 0.8 pp8.54% 0.06 pp

How to Read This Comparison

Valuation ratios (P/E, P/B) use the latest consolidated figures where available; growth numbers compare against the same period last year; shareholding percentages come from the most recent quarterly filings, with the change shown against the prior quarter. A "more favourable" highlight is relative between these two companies only — it is not a rating, a recommendation, or a comparison against the wider sector. Rows with no reported data for either company are hidden rather than shown empty.

Deep-dive each company on its stock page for quarterly results, technicals, filings and the full peer set: Cohance Lifesciences Limited and Divis Laboratories Ltd.

Data source: NSE and company filings via StockeZee. This comparison is informational — it is not investment advice, and StockeZee is not a SEBI-registered investment adviser.